HK1133012A1 - Pyrimidinones as casein kinase ii (ck2) modulators - Google Patents

Pyrimidinones as casein kinase ii (ck2) modulators

Info

Publication number
HK1133012A1
HK1133012A1 HK09112217.3A HK09112217A HK1133012A1 HK 1133012 A1 HK1133012 A1 HK 1133012A1 HK 09112217 A HK09112217 A HK 09112217A HK 1133012 A1 HK1133012 A1 HK 1133012A1
Authority
HK
Hong Kong
Prior art keywords
casein kinase
pyrimidinones
modulators
formula
pathways
Prior art date
Application number
HK09112217.3A
Other languages
English (en)
Inventor
Elena S Koltun
Patrick Kearney
Naing Aay
Arlyn Arcalas
Wai Ki Vicky Chan
Jeffry Kimo Curtis
Hongwang Du
Ping Huang
Brian Kane
Moon Hwan Kim
Michael Pack
Amy L Tsuhako
Wei Xu
Cristiana A Zaharia
Peiwen Zhou
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of HK1133012A1 publication Critical patent/HK1133012A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK09112217.3A 2007-04-25 2009-12-28 Pyrimidinones as casein kinase ii (ck2) modulators HK1133012A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92635807P 2007-04-25 2007-04-25
PCT/US2008/005419 WO2008143759A1 (en) 2007-04-25 2008-04-24 Pyrimidinones as casein kinase ii (ck2) modulators

Publications (1)

Publication Number Publication Date
HK1133012A1 true HK1133012A1 (en) 2010-03-12

Family

ID=39645308

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09112217.3A HK1133012A1 (en) 2007-04-25 2009-12-28 Pyrimidinones as casein kinase ii (ck2) modulators

Country Status (9)

Country Link
US (1) US8324231B2 (zh)
EP (1) EP2074114B1 (zh)
JP (1) JP5330375B2 (zh)
KR (1) KR20100017359A (zh)
CN (1) CN102317281A (zh)
AU (1) AU2008253684B2 (zh)
HK (1) HK1133012A1 (zh)
MX (1) MX2009011579A (zh)
WO (1) WO2008143759A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102408380B (zh) * 2011-12-22 2014-04-16 浙江大学 5-氨基嘧啶硫酮类化合物及其制备方法
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US10280156B2 (en) * 2014-08-28 2019-05-07 Medizinische Universität Wien Heteroaromatic chalcone derivatives and their medical use
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
US10227344B2 (en) 2016-06-24 2019-03-12 Polaris Pharmaceuticals, Inc. CK2 inhibitors, compositions and methods thereof
CA3030232A1 (en) * 2016-07-13 2018-01-18 Centre National De La Recherche Scientifique - Cnrs - Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
EP3672973A4 (en) 2017-08-22 2021-05-26 JS Innopharm (Shanghai) Ltd. HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
KR102337404B1 (ko) * 2020-01-03 2021-12-10 연세대학교 산학협력단 조직 재생용 조성물
CN111217862B (zh) * 2020-02-26 2023-01-31 陕西科技大学 一种4-芳基-6-二茂铁基-3,4-二氢嘧啶-2(1h)-酮的制备方法
GB202213163D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2118315C3 (de) 1970-04-20 1975-04-03 Sumitomo Chemical Co., Ltd., Osaka (Japan) 2-(1H)-Chinazolinonderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US3950526A (en) 1970-04-20 1976-04-13 Sumitomo Chemical Company, Limited Quinazoline derivatives in pharmaceutical compositions for treating pain and inflammation
CA2385349A1 (en) 1999-09-24 2001-04-05 Francis J. Giles Method for the treatment or prevention of viral infection using nucleoside analogues
WO2007048064A2 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Amino-pyrimidines as casein kinase ii (ck2) modulators
JP2009534400A (ja) * 2006-04-19 2009-09-24 ノバルティス アクチエンゲゼルシャフト インダゾール化合物およびｃｄｃ７の阻害方法
KR20100017362A (ko) * 2007-04-25 2010-02-16 엑셀리시스, 인코포레이티드 Ｐｉｍ 조절제로서 ６­페닐피리미디논

Also Published As

Publication number Publication date
US8324231B2 (en) 2012-12-04
AU2008253684B2 (en) 2014-02-27
KR20100017359A (ko) 2010-02-16
EP2074114B1 (en) 2013-03-06
MX2009011579A (es) 2009-11-11
CN102317281A (zh) 2012-01-11
EP2074114A1 (en) 2009-07-01
JP2010525068A (ja) 2010-07-22
US20100144770A1 (en) 2010-06-10
WO2008143759A1 (en) 2008-11-27
AU2008253684A1 (en) 2008-11-27
JP5330375B2 (ja) 2013-10-30

Similar Documents

Publication Publication Date Title
HK1133012A1 (en) Pyrimidinones as casein kinase ii (ck2) modulators
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
UA94622C2 (en) Kinase innhibitor
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
GEP20125564B (en) Pyrimidine derivatives as kinase inhibitors
TN2011000293A1 (en) Protein kinase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TNSN08191A1 (en) Kinase inhibitors
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
WO2009155121A3 (en) Inhibitors of pi3 kinase
MX2009008506A (es) Derivados del pirazol como inhibidores de 11-b-hsd1.
MY151986A (en) Adamantyl diamide derivatives and uses of same
SE0400284D0 (sv) Novel compounds
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
TNSN08529A1 (en) Inhibitors of akt (protein kinase b)
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2009012375A3 (en) Squarate kinase inhibitors
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
TNSN08369A1 (en) Benzimidazole derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170424